X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to cover evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer. Nykode will sponsor the trial, and Roche will provide atezolizumab.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 01, 2023
Details:
VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate targeting antigens to antigen presenting cells. It is in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Based on the positive interim data and in line with our potential registrational trial strategy, we look forward to starting the VB-C-04 trial in the U.S. The trial is aimed at providing a fast path to making VB10.16 available to patients.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GOG Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2023
Details:
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The drug candidate has reported interim data from VB-C-02, a Phase 2 trial in heavily pre-treated cervical cancer patients.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Lead Product(s): VB10.16,Pembrolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2022
Details:
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
VB10.NEO is a proprietary individualized DNA-based neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors.
Lead Product(s): VB10.NEO,Bempegaldesleukin
Therapeutic Area: Oncology Product Name: VB10.NEO
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
VB10.2210 is designed to induce T cell responses against epitopes from seven additional antigens that are highly conserved across previous and existing SARS-CoV-2 variants. VB10.2210 induced de novo T cell responses to all four non-Spike antigens.
Lead Product(s): VB10.2210
Therapeutic Area: Infections and Infectious Diseases Product Name: VB10.2210
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
VB10.16, a therapeutic vaccine and, an immunotherapy for the treatment of human papillomavirus 16 induced malignancies, is in Phase 2 for the treatment of cervical cancer.
Lead Product(s): VB10.16
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
